Lipids and Diabetic Nephropathy

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2006 Nov 23

PMID 17118229

Citations 28

Authors

Rey F Rosario

Sharma Prabhakar

Affiliations

Soon will be listed here.

Abstract

Although several factors may mediate the development and progression of diabetic nephropathy, hyperlipidemia is now considered an independent and major determinant of progression of renal disease in diabetes. The following discussion focuses on the experimental evidence that incriminates hyperlipidemia as a pathogenic factor for diabetic nephropathy and the potential mechanisms that may mediate renal injury from hyperlipidemia, as well as the clinical studies involving therapeutic interventions for hyperlipidemia and their impact on progression of diabetic renal disease.

Citing Articles

The role of advanced glycation end products between thyroid function and diabetic nephropathy and metabolic disorders.

Zhang Y, Wang Y, Kang Q, Chen Y, Ai L, Hu K Sci Rep. 2025; 15(1):7202.

PMID: 40021692 PMC: 11871035. DOI: 10.1038/s41598-025-88806-7.

Roflumilast ameliorates diabetic nephropathy in rats through down-regulation of JAK/STAT signaling pathway.

Patel P, Patel S, Chudasama P, Soni S, Raval M Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(11):3285-3297.

PMID: 37318524 DOI: 10.1007/s00210-023-02535-0.

Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes.

Guttapadu R, Korla K, Uk S, Annam V, Ashok P, Chandra N NPJ Syst Biol Appl. 2023; 9(1):18.

PMID: 37221264 PMC: 10206066. DOI: 10.1038/s41540-023-00275-8.

Renoprotective effect of JinQi-JiangTang tablet on high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats.

Jiang B, Qu Z, Gu Y, Li X, Wang J, Zhang J RSC Adv. 2022; 8(73):41858-41871.

PMID: 35558809 PMC: 9091965. DOI: 10.1039/c8ra07858k.

TGF-Beta as a Master Regulator of Diabetic Nephropathy.

Wang L, Wang H, Liu T, Lan H Int J Mol Sci. 2021; 22(15).

PMID: 34360646 PMC: 8345981. DOI: 10.3390/ijms22157881.

References

Harris K, Wheeler D, Chong C . A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int. 2002; 61(4):1469-74. DOI: 10.1046/j.1523-1755.2002.00262.x. View

Stewart K . Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA. 2002; 288(13):1622-31. DOI: 10.1001/jama.288.13.1622. View

Ravid M, Neumann L, Lishner M . Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int. 1995; 47(3):907-10. DOI: 10.1038/ki.1995.135. View

. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001; 24(8):1335-41. DOI: 10.2337/diacare.24.8.1335. View

Onuma T, Laffel L, Angelico M, Krolewski A . Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol. 1996; 7(7):1075-8. DOI: 10.1681/ASN.V771075. View

Groop P, Elliott T, Ekstrand A, Friedman R, Viberti G, Taskinen M . Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes. 1996; 45(7):974-9. DOI: 10.2337/diab.45.7.974. View

Grone H, Hohbach J, Grone E . Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl. 1996; 54:S18-22. View

Gall M, Hougaard P, Borch-Johnsen K, Parving H . Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997; 314(7083):783-8. PMC: 2126209. DOI: 10.1136/bmj.314.7083.783. View

Jerums G, Allen T, Tsalamandris C, Akdeniz A, Sinha A, Gilbert R . Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia. 1993; 36(10):1037-44. DOI: 10.1007/BF02374496. View

10.

Remuzzi G, Ruggenenti P, Benigni A . Understanding the nature of renal disease progression. Kidney Int. 1997; 51(1):2-15. DOI: 10.1038/ki.1997.2. View

11.

McFarlane S, Muniyappa R, Francisco R, Sowers J . Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002; 87(4):1451-8. DOI: 10.1210/jcem.87.4.8412. View

12.

Inman S, Stowe N, Cressman M, Brouhard B, Nally Jr J, Satoh S . Lovastatin preserves renal function in experimental diabetes. Am J Med Sci. 1999; 317(4):215-21. DOI: 10.1097/00000441-199904000-00001. View

13.

Chen H, Guh J, Chang J, Hsieh M, Shin S, Lai Y . Role of lipid control in diabetic nephropathy. Kidney Int Suppl. 2005; (94):S60-2. DOI: 10.1111/j.1523-1755.2005.09415.x. View

14.

Takemura T, Yoshioka K, AYA N, Murakami K, Matumoto A, Itakura H . Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int. 1993; 43(4):918-27. DOI: 10.1038/ki.1993.129. View

15.

Lassila M, Seah K, Allen T, Thallas V, Thomas M, Candido R . Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol. 2004; 15(8):2125-38. DOI: 10.1097/01.ASN.0000133025.23732.46. View

16.

Klein R, Klein B, Moss S, Cruickshanks K, Brazy P . The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care. 1999; 22(5):743-51. DOI: 10.2337/diacare.22.5.743. View

17.

Krane V, Wanner C . At which stage of chronic kidney disease should dyslipidemia be treated?. Nat Clin Pract Nephrol. 2006; 2(4):176-7. DOI: 10.1038/ncpneph0129. View

18.

Trovati M, Cavalot F . Optimization of hypolipidemic and antiplatelet treatment in the diabetic patient with renal disease. J Am Soc Nephrol. 2003; 15 Suppl 1:S12-20. DOI: 10.1097/01.asn.0000093238.09114.40. View

19.

Nakamura T, Kawagoe Y, Ogawa H, Ueda Y, Hara M, Shimada N . Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am J Kidney Dis. 2005; 45(1):48-53. DOI: 10.1053/j.ajkd.2004.09.013. View

20.

Werle E, Fiehn W, Hasslacher C . Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care. 1998; 21(6):994-8. DOI: 10.2337/diacare.21.6.994. View